A Phase 3 interventional study of Doravirine and Darunavir in HIV-1, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To establish a new treatment option for treatment-naïve participants with HIV-1, the efficacy and safety of doravirine will be determined relative to a protease inhibitor (PI). Participants will receive double-blind treatment during the 96-week Base Study. Eligible participants in either of the Base Study groups will continue to receive the doravirine-containing regimen open label for an additional 96 weeks in the Study Extension 1. Eligible participants who are deriving benefit will continue in Study Extension 2 to receive the doravirine-containing regimen open label until doravirine becomes locally available or for an additional 96 weeks, whichever comes first. The primary hypothesis is that doravirine 100 mg once a day (q.d.) is non-inferior to darunavir/ritonavir (800 mg/100 mg) q.d., each in combination with TRUVADA™ or EPZICOM™/KIVEXA™, as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL at Week 48. If non-inferiority is established, then the superiority of doravirine 100 mg q.d. compared to darunavir/ ritonavir (800 mg/100 mg) q.d. will be assessed.
Participants in Australia, Russia, and South Africa who are deriving benefit from MK-1439A are also eligible to continue receiving study drug during Study Extension 3, which will last for 2 years or until drug is available locally, whichever comes first.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the Doravirine regimen in Study Extension 2 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first. Eligible participants may continue to receive the Doravirine regimen in Study Extension 3 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
Drug: Doravirine · Drug: TRUVADA™ or EPZICOM™/KIVEXA™
Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for an additional 96 weeks. Eligible participants may continue to receive the Doravirine regimen in Study Extension 2 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first. Eligible participants may continue to receive the Doravirine regimen in Study Extension 3 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
Drug: Doravirine · Drug: Darunavir · Drug: Ritonavir · Drug: TRUVADA™ or EPZICOM™/KIVEXA™
Doravirine 100 mg tablet administered p.o. q.d.
Darunavir 800 mg tablet administered p.o. q.d.
Ritonavir 100 mg tablet administered p.o. q.d.
The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.
Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48
The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
Time frame: Week 48
Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 96
The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
Time frame: Week 96
Change From Baseline in Mean CD4+ T-cell Count at Week 48
CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.
Time frame: Baseline and Week 48
Change From Baseline in Mean CD4+ T-cell Count at Week 96
CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.
Time frame: Baseline and Week 96
Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48
Serum LDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid-lowering therapy.
Time frame: Baseline and Week 48
Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48
Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
Time frame: Baseline and Week 48
Mean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48
Serum HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
Time frame: Baseline and Week 48
Mean Change From Baseline in Fasting Total Cholesterol at Week 48
Serum total cholesterol was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
Time frame: Baseline and Week 48
Mean Change From Baseline in Fasting Triglyceride at Week 48
Serum triglyceride was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
Time frame: Baseline and Week 48
Percentage of Participants With Any Adverse Event
An adverse event (AE) is defined as any untoward medical occurrence in a study participant and which does not necessarily have to have a causal relationship to treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the study treatment or protocol-specified procedure, whether or not considered related to study treatment or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study treatment is also an AE. The percentage of participants with any AE was assessed.
Time frame: Up to 98 weeks
Percentage of Participants With Any Serious Adverse Event
A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.
Time frame: Up to 98 weeks
Percentage of Participants With Any Drug-related Adverse Event
The investigator was to determine if an AE had a reasonable possibility of a relationship to the study drug. The percentage of participants with any drug-related AE was assessed.
Time frame: Up to 98 weeks
Percentage of Participants With Any Drug-related Serious Adverse Event
The percentage of participants with any drug-related SAE was assessed.
Time frame: Up to 98 weeks
Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event
The percentage of participants who discontinued study treatment due to an AE was assessed.
Time frame: Up to 96 weeks
Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 48
The percentage of participants in each arm achieving HIV-1 RNA levels \<40 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
Time frame: Week 48
Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 96
The percentage of participants in each arm achieving HIV-1 RNA levels \<40 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
Time frame: Week 96
| Milestone | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg |
|---|---|---|
| Started | 385 | 384 |
| Treated | 383 | 383 |
| Completed | 292 | 273 |
| Not completed | 93 | 111 |
| Withdrew: Adverse event | 6 | 14 |
| Withdrew: Death | 3 | 1 |
| Withdrew: Lack of efficacy | 21 | 32 |
| Withdrew: Lost to follow-up | 28 | 24 |
| Withdrew: Protocol violation | 1 | 6 |
| Withdrew: Withdrawal by subject | 19 | 22 |
| Withdrew: Noncompliance with drug | 9 | 6 |
| Withdrew: Physician decision | 2 | 4 |
| Withdrew: Pregnancy | 2 | 1 |
| Withdrew: Randomized not treated | 2 | 1 |
| Milestone | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg |
|---|---|---|
| Started | 259 | 233 |
| Completed | 210 | 190 |
| Not completed | 49 | 43 |
| Withdrew: Adverse event | 6 | 1 |
| Withdrew: Availability of study medication locally | 2 | 0 |
| Withdrew: Lack of efficacy | 8 | 11 |
| Withdrew: Lost to follow-up | 8 | 7 |
| Withdrew: Non-compliance with study drug | 1 | 2 |
| Withdrew: Physician decision | 3 | 7 |
| Withdrew: Pregnancy | 2 | 1 |
| Withdrew: Withdrawal by subject | 19 | 14 |
| Milestone | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg |
|---|---|---|
| Started | 148 | 129 |
| Completed | 101 | 91 |
| Not completed | 47 | 38 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Availability of study medication locally | 38 | 29 |
| Withdrew: Lack of efficacy | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Non-compliance with study drug | 2 | 0 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Milestone | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg |
|---|---|---|
| Started | 50 | 36 |
| Completed | 36 | 23 |
| Not completed | 14 | 13 |
| Withdrew: Availability of study medication locally | 6 | 6 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Non-compliance with study drug | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 2 |
The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
| Percentage of participants | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48 | 83.8 | 79.9 |
The percentage of participants in each arm achieving HIV-1 RNA levels \<50 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
| Percentage of participants | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 96 | 73.1 | 66.0 |
CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.
| Cells/mm^3 | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Change From Baseline in Mean CD4+ T-cell Count at Week 48 | 192.7 (171.5 to 213.9) | 185.6 (167.5 to 203.6) |
CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.
| Cells/mm^3 | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Change From Baseline in Mean CD4+ T-cell Count at Week 96 | 224.1 (200.8 to 247.4) | 206.7 (184.9 to 228.5) |
Serum LDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid-lowering therapy.
| mg/dL | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Baseline | 91.10 ± 28.61 | 91.76 ± 30.36 |
| Change from Baseline | -4.51 ± 20.64 | 9.92 ± 27.31 |
Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
| mg/dL | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Baseline | 113.34 ± 34.25 | 114.44 ± 35.01 |
| Change from Baseline | -5.30 ± 23.28 | 13.75 ± 31.08 |
Serum HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
| mg/dL | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Baseline | 43.58 ± 12.99 | 43.27 ± 13.96 |
| Change from Baseline | 3.94 ± 10.66 | 4.15 ± 11.01 |
Serum total cholesterol was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
| mg/dL | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg |
|---|---|---|
| Baseline | 156.92 ± 35.82 | 157.71 ± 37.34 |
| Change from Baseline | -1.37 ± 25.47 | 17.90 ± 33.95 |
Serum triglyceride was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
| mg/dL | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Baseline | 111.16 ± 75.31 | 117.02 ± 97.30 |
| Change from Baseline | -3.14 ± 68.81 | 21.97 ± 92.59 |
An adverse event (AE) is defined as any untoward medical occurrence in a study participant and which does not necessarily have to have a causal relationship to treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the study treatment or protocol-specified procedure, whether or not considered related to study treatment or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study treatment is also an AE. The percentage of participants with any AE was assessed.
| Percentage of participants | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Percentage of Participants With Any Adverse Event | 84.6 | 82.8 |
A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.
| Percentage of participants | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Percentage of Participants With Any Serious Adverse Event | 7.0 | 8.6 |
The investigator was to determine if an AE had a reasonable possibility of a relationship to the study drug. The percentage of participants with any drug-related AE was assessed.
| Percentage of participants | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Percentage of Participants With Any Drug-related Adverse Event | 32.1 | 32.1 |
The percentage of participants with any drug-related SAE was assessed.
| Percentage of participants | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Percentage of Participants With Any Drug-related Serious Adverse Event | 0.3 | 0.3 |
The percentage of participants who discontinued study treatment due to an AE was assessed.
| Percentage of participants | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event | 1.6 | 3.4 |
The percentage of participants in each arm achieving HIV-1 RNA levels \<40 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
| Percentage of participants | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 48 | 83.3 | 79.1 |
The percentage of participants in each arm achieving HIV-1 RNA levels \<40 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
| Percentage of participants | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg |
|---|---|---|
| Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 96 | 72.0 | 64.4 |
Collected over Up to Week 386. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doravirine 100 mg | 3/385 (0.8%) | 45/383 (11.7%) | 264/383 (68.9%) |
| Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg | 3/384 (0.8%) | 49/383 (12.8%) | 247/383 (64.5%) |
| Event | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg |
|---|---|---|
| AppendicitisInfections and infestations | 2/383 | 1/383 |
| Post procedural infectionInfections and infestations | 0/383 | 2/383 |
| TuberculosisInfections and infestations | 0/383 | 2/383 |
| Femur fractureInjury, poisoning and procedural complications | 2/383 | 0/383 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/383 | 2/383 |
| Back painMusculoskeletal and connective tissue disorders | 0/383 | 2/383 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/383 | 2/383 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/383 | 1/383 |
| NeutropeniaBlood and lymphatic system disorders | 0/383 | 1/383 |
| Myocardial infarctionCardiac disorders | 1/383 | 0/383 |
| Event | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 72/383 | 100/383 |
| Upper respiratory tract infectionInfections and infestations | 64/383 | 40/383 |
| HeadacheNervous system disorders | 63/383 | 59/383 |
| NasopharyngitisInfections and infestations | 61/383 | 61/383 |
| NauseaGastrointestinal disorders | 52/383 | 54/383 |
| SyphilisInfections and infestations | 29/383 | 39/383 |
| FatigueGeneral disorders | 38/383 | 28/383 |
| CoughRespiratory, thoracic and mediastinal disorders | 38/383 | 14/383 |
| BronchitisInfections and infestations | 31/383 | 37/383 |
| Back painMusculoskeletal and connective tissue disorders | 37/383 | 13/383 |
| Age, Continuous(Years) | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg | Total |
|---|---|---|---|
| Mean | 34.9 ± 10.7 | 35.7 ± 10.7 | 35.3 ± 10.7 |
| Sex: Female, Male(Participants) | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg | Total |
|---|---|---|---|
| Female | 65 | 58 | 123 |
| Male | 320 | 326 | 646 |
| Ethnicity (NIH/OMB)(Participants) | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 93 | 86 | 179 |
| Not Hispanic or Latino | 286 | 291 | 577 |
| Unknown or Not Reported | 6 | 7 | 13 |
| Race (NIH/OMB)(Participants) | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 3 | 6 |
| Asian | 7 | 7 | 14 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 3 |
| Black or African American | 87 | 89 | 176 |
| White | 281 | 280 | 561 |
| More than one race | 6 | 2 | 8 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Mean Cluster of Differentiation 4 (CD4+) T-cell Count(Cells/mm^3) | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg | Total |
|---|---|---|---|
| Mean | 432.6 ± 208.4 | 411.9 ± 229.6 | 422.2 ± 219.4 |
| Plasma HIV-1 RNA(Copies/mL) | Doravirine 100 mg | Daurunavir 800 mg + Ritonavir 100 mg | Total |
|---|---|---|---|
| Median | 27073.0 (105 to 2776658) | 27357.0 (235 to 3272236) | 27073.0 (105 to 3272236) |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2014 to primary completion in Sep 2016, 21 months.
Results were first posted in Oct 2018, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doravirine